Hoffmann-la Roche Inc.

Curis, Inc.

F. Hoffmann-la Roche Ag

Petra Rueger

Christian Klein

Wolfgang Schaefer

Sabine Imhof-Jung

Laurent Lariviere

Harald Duerr

Joerg Thomas Regula

Michael Molhoj

Ulrich Goepfert

Hubert Hertenberger

Tilman Schlothauer

Sebastian Fenn

Stefan Seeber

Stefan Scheiblich

Kurt Lang

Konrad Honold

Matthias Rueth

Bernhard Goller

Angelika Esswein

Ekkehard Moessner

Guy Georges

Anja Limberg

Klaus-Peter Kuenkele

Richard Engh

Manfred Schwaiger

Birgit Masjost

Tilman Seytter

Pablo Umana

Frederick Arthur Brookfield

Olaf Mundigl

Edward Andrew Boyd

Wolfgang Von Der Saal

Hans-Willi Krell

Jens Niewoehner

Roberto Falkenstein

Ulrike Reiff

Georg Tiefenthaler

Stefan Weigand

Manfred Kubbies

Maria Amann

Thomas Von Hirschheydt

Gang Xu

Alexander Bujotzek

Roland Staack

Johannes Sam

Adrian Hugenmatter

Alexander Knaupp

Joerg Zielonka

Francesca Ros

Christine Schuell

Birgit Weydanz

Justin Warne

Estelle Marrer-Berger

Cuiying Shao

Laurene Pousse

Thomas Kraft

Sabine Huensch

Dietrich Tuerck

Janine Faigle

Carina Cantrill

Juergen Peter Bachl

Thorsten Hoevel

Stefan Koch

Aude Lemarchand

Tilmann Seytter

Georges Guy

Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.

Bispecific anti-human A-beta/anti-human transferrin receptor antibodies

Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.

Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use

The present invention relates to methods for separating multispecific CrossMab antibodies from light chain mispaired variants thereof in a solution comprising CrossMab bispecific antibodies and mispaired antibody variants thereof by hydrophobic interaction chromatography.

Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography

Herein is reported the use of an immobilized non-covalent complex of a neonatal Fc receptor (FcRn) and beta-2-microglobulin (b2m) as affinity chromatography ligand in general and, for example, for the determination of the in vivo half-live of an antibody by determining the ratio of the retention times of the antibody and a reference antibody.

Fc-receptor based affinity chromatography

Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.

Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use

The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules targeting OX40 and FAP

Herein is reported a fusion polypeptide according to formula I (TAG-X1-C1qA-X2-C1qB-X3-C1qC-X4), comprising a fragment of SEQ ID NO: 01 (C1qA), a fragment of SEQ ID NO: 03 (C1qB), a fragment of SEQ ID NO: 05 (C1qC) and optionally a tag (TAG).

Complement factor based affinity chromatography

Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).

Monovalent blood brain barrier shuttle modules

Herein is a fusion polypeptide with the formula R1-FC-R2, wherein R1 denotes a first Fc-receptor, R2 denotes a second Fc-receptor, and FC denotes a heavy chain Fc-region polypeptide, wherein R1 or R2 or both are present, wherein FC does not substantially bind to R1 and/or R2 and uses thereof.

Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereof

The present invention relates to novel amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, to a process for their manufacture, medicaments containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents. The present derivatives are new compounds of the general formula (I). 

Amide derivatives of 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents

The present invention relates to novel amide derivatives of 7-amino-3-phenyl dihydropyrimido[4,5-d]pyrimidinones, to a process for their manufacture, medicaments containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents. The present derivatives are new compounds of the general formula (I). 

Amide derivatives of 7-amino-3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents

The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Aminopyrazole derivatives

Growing community of inventors

Penzberg, Germany

Petra Rueger